ArticlePloS one2020
Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Gut microbiota: A key player for soluble dietary fiber in regulating inflammatory disease.Journal of advanced research · 2026Review
- Modulation of Gut Microbes and Hepatic Metabolites by PCP Ameliorates NASH and Fatigue-like Performance in Mice.Nutrients · 2025Article
- Natural polysaccharides with the reduction of intestinal barrier damage in cardiovascular diseases.Molecular and cellular biochemistry · 2025Review
- Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study.Frontiers in medicine · 2025Article
- Immunopharmacological Insights intoCurrent pharmaceutical design · 2025Review
- The impact of traditional Chinese medicine and dietary compounds on modulating gut microbiota in hepatic fibrosis: A review.Heliyon · 2024Review
- Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.European journal of medical research · 2024Review
- The gut-liver axis in fatty liver disease: role played by natural products.Frontiers in pharmacology · 2024Review
- Dietary supplementation with Acremonium terricola culture alters the gut microbial structure and improves the growth performance, antioxidant status, and immune function of weaning piglets.BMC veterinary research · 2023Article
- Recent advances in the extraction, purification, structural-property correlations, and antiobesity mechanism of traditional Chinese medicine-derived polysaccharides: a review.Frontiers in nutrition · 2023Review
- Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota.Frontiers in oncology · 2023Review
- "Get the best out of what comes in" - adaptation of the microbiota of chamois (Frontiers in microbiology · 2023Article
- The Regulatory Roles of Polysaccharides and Ferroptosis-Related Phytochemicals in Liver Diseases.Nutrients · 2022Review
- Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases.Frontiers in microbiology · 2022Review
- Dietary supplementation withFrontiers in immunology · 2022Article
- Mushroom polysaccharides with potential in anti-diabetes: Biological mechanisms, extraction, and future perspectives: A review.Frontiers in nutrition · 2022Review
- Multispecies probiotics alter fecal short-chain fatty acids and lactate levels in weaned pigs by modulating gut microbiota.Journal of animal science and technology · 2021Article
- Polysaccharides Obtained fromFoods (Basel, Switzerland) · 2021Article
- Therapeutic Properties of Edible Mushrooms and Herbal Teas in Gut Microbiota Modulation.Microorganisms · 2021Review
- Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value.Journal of fungi (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various dietary fibers are considered to prevent obesity by modulating the gut microbiota. Cordyceps sinensis polysaccharide (CSP) is a soluble dietary fiber known to have protective effects against obesity and related diseases, but whether these effects induce any side effects remains unknown. The function and safety of CSP were tested in high-fat diet (HFD)-feding C57BL/6J mice. The results revealed that even though CSP supplementation could prevent an increase in body weight, it aggravated liver fibrosis and steatosis as evidenced by increased inflammation, lipid metabolism markers, insulin resistance (IR) and alanine aminotransferase (ALT) in HFD-induced obesity. 16S rDNA gene sequencing was used to analyze the gut microbiota composition, and the relative abundance of the Actinobacteria phylum, including the Olsenella genus, was significantly higher in CSP-treated mice than in HFD-fed mice. CSP supplementation may increase the proportion of Actinobacteria, which can degrade CSP. The high level of Actinobacteria aggravated the disorder of the intestinal flora and contributed to the progression from obesity to nonalcoholic steatohepatitis (NASH) and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.